Dr. Joyce E. Yu, MD
Allergy & Immunology (Allergy & Immunology Physician)
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: Icahn School of Medicine at Mount Sinai
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
NY license 235923 -
Pediatric Allergy/Immunology Physician
NY license 235923
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Trustees of Columbia University in The City of New York (2,296 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 13 companies reported 63 payments worth $10,782 in total to this clinician.
| Csl Behring | $8,259 |
|---|---|
| Genzyme Corporation | $947 |
| Ars Pharmaceuticals Operations, Inc. | $394 |
| AstraZeneca Pharmaceuticals LP | $250 |
| GlaxoSmithKline, LLC. | $217 |
| Novartis Pharmaceuticals Corporation | $183 |
| Amgen Inc. | $148 |
| Regeneron Healthcare Solutions, Inc. | $104 |
| Consulting Fee | $4,494 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $3,236 |
| Food and Beverage | $2,944 |
| Education | $108 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Csl Behring Oct 15, 2025 | Consulting Fee Andembry · Hematology | $4,494 |
| Csl Behring Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology | $1,438 |
| Csl Behring Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology | $1,079 |
| Csl Behring Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) Andembry · Hematology | $719 |
| Sanofi-aventis U.S. LLC Dec 13, 2025 | Education DUPIXENT · Immunology · in-kind | $99.99 |
| Genzyme Corporation Jun 16, 2025 | Education DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $8.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $21,109 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
Sanofi US Services Inc. · Completed · NCT05526521 - A One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) at Multiple Dose Levels in Adult Participants With Peanut Allergy
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.